Developer docs
API playgroundTry for free, no card

Search company profiles

Launch Therapeutics

Full company profile

uuid00066dy

Namestring
Launch Therapeutics
Legal namestring
Launch Therapeutics, Inc.
Websiteurl
launchtx.com
Company typeenum
Private
Founded yearint
2022
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical co-development, drug development services, clinical trial operations, pharmaceutical partnerships, development financing
Industry2 codes
PRIMARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code1 code
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Clinical Development Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Clinical Co-Development Services
TypeProfessional Services
Description

Launch Tx provides operational execution and management of clinical trials for pharmaceutical partners. They receive payment for performing services in accordance with co-development agreements. Partners gain access to strategic guidance, operational resources, and development funding.

launchtx.com
2Development Financing
TypeLicensing Royalties
Description

Abingworth (backed by Carlyle) provides development funding to offset program costs for partnered companies. In return, Abingworth receives fixed payments upon regulatory approval and success payments based on sales.

carlyle.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Launch Therapeutics provides clinical co-development services to pharmaceutical and biotechnology companies, taking the lead role in operational execution and management of late-stage (Phase 3) clinical trials. The company pairs deep drug development, medical, regulatory, and clinical operations expertise with development financing from its backers Carlyle and Abingworth, structuring co-development agreements in which partners retain manufacturing, regulatory interactions, and commercialization responsibilities.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 6 Phase III studies completed or underway
+3 more records
Product overview1 text field

Launch Therapeutics is a clinical development company offering innovative co-development models that combine access to capital with deep drug development, medical, clinical operations, regulatory, and commercialization expertise. The company provides clinical co-development services to pharmaceutical and biotech companies through various models including clinical co-development (CCD) investments, risk financing, and full in-licensing arrangements. Key co-development partnerships include the TEV-'248 ICS-SABA asthma rescue inhaler program with Teva, the TRODELVY NSCLC program with Gilead, and the upacicalcet Phase 3 program with Pathalys Pharma. Founded in 2022 and backed by Carlyle and Abingworth, Launch Tx focuses on late-stage clinical assets, having supported 6 Phase III studies across 955+ sites in 85+ countries with 4,200+ patients.

Product and service4 records
1Clinical Co-Development Services
CategoryClinical Development Services
Description

Operational execution and management of late-stage (Phase 3) clinical trials for pharmaceutical and biotech partners, combining strategic guidance, clinical development plan validation, feasibility assessment, and access to development capital under custom co-development agreements.

2TEV-'248 (ICS/SABA) Asthma Rescue Inhaler Program
CategoryCo-development Partnership Program
Description

Co-development program with Teva Pharmaceutical Industries for a dual-action ICS/SABA (fluticasone propionate and albuterol sulfate) multidose dry powder rescue inhaler for the reduction and prevention of asthma exacerbations, with Launch Tx leading operational execution and management of the clinical trials.

3TRODELVY (sacituzumab govitecan-hziy) NSCLC Program
CategoryCo-development Partnership Program
Description

Clinical collaboration program with Gilead Sciences supporting select clinical studies of TRODELVY, a first-in-class Trop-2-directed antibody-drug conjugate, in non-small cell lung cancer, governed by a Joint Steering Committee with development leadership from Launch Tx.

4Upacicalcet (PLS240) Phase 3 Program
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-04-01
Description

Clinical collaboration agreement for TEV-'248 (ICS/SABA) dual-action asthma rescue inhaler program. Launch Tx has lead role in operational execution and management of planned clinical trials. Investors committed up to $150 million in funding to offset program costs. Teva retains primary responsibility for manufacturing, regulatory interactions in the U.S., and commercialization. Joint Steering Committee established with executive leadership from both organizations.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-02-29
Description

Clinical collaboration agreement establishing Joint Steering Committee to support select clinical studies of TRODELVY® (sacituzumab govitecan-hziy) within non-small cell lung cancer. Investors committed up to $210 million in funding to support clinical studies. Gilead retains full rights to Trodelvy and if development is successful, Abingworth would receive fixed payment upon regulatory approval and royalty payments based on U.S. net sales.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-18
Description

Strategic collaboration to advance upacicalcet (PLS240) through pivotal Phase 3 studies for treatment of secondary hyperparathyroidism (SHPT) in patients on hemodialysis. Investors committed $150 million through secured product financing and equity to support Phase 3 trials, registration efforts, and pre-commercialization activities. Launch Tx has lead role in operational execution and management of clinical trials.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-08-15
Description

Partnership to advance OPT-302, a promising therapy for wet age-related macular degeneration (wet AMD). Opthea secured up to US$170 million in non-dilutive financing to support the development program.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Medpace is a mid-to-large CRO focused on full-service clinical development for small and mid-sized biopharma. Its operational model overlaps significantly with the trial execution work Launch Tx performs for partners.

TypeBroad incumbent
Description

PPD is a major global CRO providing clinical development services to pharma and biotech, now owned by Thermo Fisher. It is a comparable clinical operations services provider with similar late-stage trial execution capabilities, though structured as a traditional CRO rather than a co-development financier.

TypeDirect peer
Description

HCR is a healthcare-focused royalty and structured financing firm that provides capital against late-stage development and commercial assets. It competes with Launch Tx/Abingworth in sourcing structured development financing deals against pharma and biotech assets.

TypeBroad incumbent
Description

IQVIA is one of the world's largest CROs and clinical development services providers. It offers the operational execution and clinical trial management services that Launch Tx either delivers directly or orchestrates through vendors, making it a broad incumbent against which Launch Tx positions itself as a more focused, capital-aligned alternative.

TypeBroad incumbent
Description

Parexel is a global CRO providing clinical trial design, execution, and regulatory services. It is a broad incumbent serving the same pharmaceutical and biotech clients that Launch Tx targets.

TypeBroad incumbent
Description

ICON is one of the largest global CROs, offering end-to-end clinical development services across all phases. It competes with Launch Tx for clinical operations work and represents the incumbent services model that Launch Tx's co-development approach seeks to disrupt.

TypeOthers
Description

Abingworth is Launch Tx's sister/parent life-sciences investment firm and the source of all development financing for its co-development deals. It is thematically the same investment thesis but operates as the financial capital provider, whereas Launch Tx is the operational execution vehicle.

TypeBroad incumbent
Description

Charles River provides early-stage and preclinical CRO services, and through its broader portfolio also competes for late-stage clinical work. It is an established life-sciences services incumbent with comparable customers.

TypeDirect peer
Description

NovaQuest is a clinical co-development financing firm that partners with biotech and pharma to fund late-stage clinical development in exchange for milestones and royalties. It is one of the longest-standing players in the same asset-financing and co-development niche as Launch Tx, with comparable deal structures.

TypeDirect peer
Description

SFJ is the closest direct peer: a clinical co-development financing company structured similarly to Launch Tx, with a model of providing development capital and operational support in exchange for milestone and royalty payments. Launch Tx's President/COO (Jonathan DeBenedetto) and several board members came directly from SFJ, and the business models are essentially identical.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Launch Therapeutics

Clinical Development Serviceslaunchtx.com

Launch Therapeutics firmographics

Firmographics
Name
Launch Therapeutics
Legal name
Launch Therapeutics, Inc.
Website
https://launchtx.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Launch Therapeutics industry classification

Industry
Product category
Clinical Development Services
NAICS
Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Clinical co-development
  • Drug development services
  • Clinical trial operations
  • Pharmaceutical partnerships
  • Development financing

Where Launch Therapeutics is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Launch Therapeutics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. Clinical Co-Development Services: Launch Tx provides operational execution and management of clinical trials for pharmaceutical partners. They receive payment for performing services in accordance with co-development agreements. Partners gain access to strategic guidance, operational resources, and development funding.
  2. Development Financing: Abingworth (backed by Carlyle) provides development funding to offset program costs for partnered companies. In return, Abingworth receives fixed payments upon regulatory approval and success payments based on sales.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Launch Therapeutics product offering

Product offering

Core offering

Launch Therapeutics provides clinical co-development services to pharmaceutical and biotechnology companies, taking the lead role in operational execution and management of late-stage (Phase 3) clinical trials. The company pairs deep drug development, medical, regulatory, and clinical operations expertise with development financing from its backers Carlyle and Abingworth, structuring co-development agreements in which partners retain manufacturing, regulatory interactions, and commercialization responsibilities.

Product overview

Launch Therapeutics is a clinical development company offering innovative co-development models that combine access to capital with deep drug development, medical, clinical operations, regulatory, and commercialization expertise. The company provides clinical co-development services to pharmaceutical and biotech companies through various models including clinical co-development (CCD) investments, risk financing, and full in-licensing arrangements. Key co-development partnerships include the TEV-'248 ICS-SABA asthma rescue inhaler program with Teva, the TRODELVY NSCLC program with Gilead, and the upacicalcet Phase 3 program with Pathalys Pharma. Founded in 2022 and backed by Carlyle and Abingworth, Launch Tx focuses on late-stage clinical assets, having supported 6 Phase III studies across 955+ sites in 85+ countries with 4,200+ patients.

Differentiator

Problem solved

Functional benefit

Products and services

  • Clinical Co-Development Services Operational execution and management of late-stage (Phase 3) clinical trials for pharmaceutical and biotech partners, combining strategic guidance, clinical development plan validation, feasibility assessment, and access to development capital under custom co-development agreements.
  • TEV-'248 (ICS/SABA) Asthma Rescue Inhaler Program Co-development program with Teva Pharmaceutical Industries for a dual-action ICS/SABA (fluticasone propionate and albuterol sulfate) multidose dry powder rescue inhaler for the reduction and prevention of asthma exacerbations, with Launch Tx leading operational execution and management of the clinical trials.
  • TRODELVY (sacituzumab govitecan-hziy) NSCLC Program Clinical collaboration program with Gilead Sciences supporting select clinical studies of TRODELVY, a first-in-class Trop-2-directed antibody-drug conjugate, in non-small cell lung cancer, governed by a Joint Steering Committee with development leadership from Launch Tx.
  • Upacicalcet (PLS240) Phase 3 Program

Quantifiable outcome

  • 6 Phase III studies completed or underway
  • +3 more outcomes

Companies that use Launch Therapeutics

Customer profile

Named customers4 records

Segments2 records

Ideal customer profiles2 records

Launch Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Launch Therapeutics partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • Teva Pharmaceutical IndustriescoreStrategic or Co-development Partner · 1 April 2024Clinical collaboration agreement for TEV-'248 (ICS/SABA) dual-action asthma rescue inhaler program. Launch Tx has lead role in operational execution and management of planned clinical trials. Investors committed up to $150 million in funding to offset program costs. Teva retains primary responsibility for manufacturing, regulatory interactions in the U.S., and commercialization. Joint Steering Committee established with executive leadership from both organizations.
  • Gilead SciencescoreStrategic or Co-development Partner · 29 February 2024Clinical collaboration agreement establishing Joint Steering Committee to support select clinical studies of TRODELVY® (sacituzumab govitecan-hziy) within non-small cell lung cancer. Investors committed up to $210 million in funding to support clinical studies. Gilead retains full rights to Trodelvy and if development is successful, Abingworth would receive fixed payment upon regulatory approval and royalty payments based on U.S. net sales.
  • Pathalys PharmacoreStrategic or Co-development Partner · 18 January 2023Strategic collaboration to advance upacicalcet (PLS240) through pivotal Phase 3 studies for treatment of secondary hyperparathyroidism (SHPT) in patients on hemodialysis. Investors committed $150 million through secured product financing and equity to support Phase 3 trials, registration efforts, and pre-commercialization activities. Launch Tx has lead role in operational execution and management of clinical trials.
  • OptheacoreStrategic or Co-development Partner · 15 August 2022Partnership to advance OPT-302, a promising therapy for wet age-related macular degeneration (wet AMD). Opthea secured up to US$170 million in non-dilutive financing to support the development program.

Scale indicators5 records

Recent moves8 records

Expansion highlights5 records

Launch Therapeutics competitors and assessment

Company assessment

Broad incumbents

  • Medpace Holdings: Medpace is a mid-to-large CRO focused on full-service clinical development for small and mid-sized biopharma. Its operational model overlaps significantly with the trial execution work Launch Tx performs for partners.
  • PPD (Thermo Fisher Scientific): PPD is a major global CRO providing clinical development services to pharma and biotech, now owned by Thermo Fisher. It is a comparable clinical operations services provider with similar late-stage trial execution capabilities, though structured as a traditional CRO rather than a co-development financier.
  • IQVIA: IQVIA is one of the world's largest CROs and clinical development services providers. It offers the operational execution and clinical trial management services that Launch Tx either delivers directly or orchestrates through vendors, making it a broad incumbent against which Launch Tx positions itself as a more focused, capital-aligned alternative.
  • Parexel International: Parexel is a global CRO providing clinical trial design, execution, and regulatory services. It is a broad incumbent serving the same pharmaceutical and biotech clients that Launch Tx targets.
  • ICON plc: ICON is one of the largest global CROs, offering end-to-end clinical development services across all phases. It competes with Launch Tx for clinical operations work and represents the incumbent services model that Launch Tx's co-development approach seeks to disrupt.
  • Charles River Laboratories: Charles River provides early-stage and preclinical CRO services, and through its broader portfolio also competes for late-stage clinical work. It is an established life-sciences services incumbent with comparable customers.

Direct peers

  • HealthCare Royalty Partners: HCR is a healthcare-focused royalty and structured financing firm that provides capital against late-stage development and commercial assets. It competes with Launch Tx/Abingworth in sourcing structured development financing deals against pharma and biotech assets.
  • NovaQuest: NovaQuest is a clinical co-development financing firm that partners with biotech and pharma to fund late-stage clinical development in exchange for milestones and royalties. It is one of the longest-standing players in the same asset-financing and co-development niche as Launch Tx, with comparable deal structures.
  • SFJ Pharmaceuticals: SFJ is the closest direct peer: a clinical co-development financing company structured similarly to Launch Tx, with a model of providing development capital and operational support in exchange for milestone and royalty payments. Launch Tx's President/COO (Jonathan DeBenedetto) and several board members came directly from SFJ, and the business models are essentially identical.

Others

  • Abingworth: Abingworth is Launch Tx's sister/parent life-sciences investment firm and the source of all development financing for its co-development deals. It is thematically the same investment thesis but operates as the financial capital provider, whereas Launch Tx is the operational execution vehicle.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Launch Therapeutics social profiles

Digital presence

Launch Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Launch Therapeutics leadership team

Management profile

Number of profiles

Profiles12 records

Launch Therapeutics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Launch Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Launch Therapeutics

What does Launch Therapeutics do?

Launch Therapeutics provides clinical co-development services to pharmaceutical and biotechnology companies, taking the lead role in operational execution and management of late-stage (Phase 3) clinical trials. The company pairs deep drug development, medical, regulatory, and clinical operations expertise with development financing from its backers Carlyle and Abingworth, structuring co-development agreements in which partners retain manufacturing, regulatory interactions, and commercialization responsibilities.

Is Launch Therapeutics a public or private company?

Launch Therapeutics is a private company. It is classified as private equity controlled and is currently operating.

When was Launch Therapeutics founded?

Launch Therapeutics was founded in 2022. It employs 11 to 50 people.

Where is Launch Therapeutics based?

Launch Therapeutics is headquartered in Boston, United States, in the North America region.

How does Launch Therapeutics make money?

Two revenue lines are on record. Clinical Co-Development Services are the primary driver. The others are development Financing.

Who are Launch Therapeutics's main competitors?

Broad incumbents on record are Medpace Holdings, PPD (Thermo Fisher Scientific), IQVIA, Parexel International, ICON plc and Charles River Laboratories. Direct peers are HealthCare Royalty Partners, NovaQuest and SFJ Pharmaceuticals. Abingworth is listed as an others.

Does Launch Therapeutics have an API?

No public API is recorded for Launch Therapeutics.

What industry is Launch Therapeutics in?

Launch Therapeutics's product category is Clinical Development Services. Its primary akta.pro industry code is HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution), with a secondary code of HLAIALAH, Regulatory Strategy & IND/NDA/BLA Submissions Support. Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comGlobal Factors Influencing the Rapid Evolution of the Fixed-Dose Combination Inhalers MarketThe fixed-dose combination inhalers market is projected to reach $22.83 billion by 2030 with a 10% CAGR, driven by innovations in triple and multi-drug inhalers, expanding chronic respiratory disease management programs, and growing telehealth adoption. In April 2024, US-based Launch Therapeutics Inc. partnered with Teva Pharmaceutical Industries Ltd. to accelerate development of a dual-action asthma rescue inhaler (ICS-SABA/TEV-'248), potentially the first fixed-dose combination inhaler of its kind. Lupin Limited launched Vilfuro G, a fixed-dose triple combination inhaler for COPD, in November 2023, offering once-daily dosing for moderate to severe COPD patients.Business Wire BlogClinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-’248) Respiratory Program; Teva and Abingworth EnterTeva and Launch Therapeutics signed a clinical collaboration to accelerate development of its ICS-SABA asthma inhaler (TEV-248). Abingworth provided up to $150 million in development funding, with Launch Therapeutics leading clinical trials. Teva retains manufacturing, U.S. regulatory, and commercialization rights.GlobeNewswireAbingworth Announces a Strategic Development Financing Agreement with Gilead Sciences; Establishes Joint Steering Committee between Launch Therapeutics and Gilead SciencesAbingworth announced a strategic development financing agreement with Gilead Sciences, providing up to $210 million for Trodelvy clinical studies in non-small cell lung cancer. Launch Therapeutics and Gilead established a joint steering committee, with Gilead retaining full rights and Abingworth receiving a fixed payment and royalties upon regulatory approval.AbingworthAbingworth Announces a Strategic Development Financing Agreement with Gilead Sciences; Establishes Joint Steering Committee between Launch Therapeutics and Gilead SciencesAbingworth announced a strategic development financing agreement with Gilead Sciences to provide up to $210 million for clinical studies of Trodelvy in non-small cell lung cancer. Launch Therapeutics, backed by Abingworth and Carlyle, entered into a clinical collaboration with Gilead to establish a Joint Steering Committee for the drug's development.PR NewswirePathalys Pharma and Launch Therapeutics Announce First Patient Enrolled Ahead of Schedule in Pivotal Phase 3 Program for Upacicalcet in Patients Receiving HemodialysisPathalys Pharma and Launch Therapeutics have enrolled the first patient ahead of schedule in the PATH Phase 3 clinical program evaluating upacicalcet for treating secondary hyperparathyroidism in end-stage kidney disease patients on hemodialysis. The PATH program consists of two identical Phase 3 trialsrandomizing approximately 375 patients each (2:1 to upacicalcet or placebo), with upacicalcet administered as a bolus IV injection at the end of dialysis sessions. Upacicalcet is a novel calcimimetic already approved in Japan in 2021, and the companies aim to accelerate its registration in the US.PR NewswirePathalys Pharma Raises $150 Million in Secured Product Financing and Equity led by Abingworth; Forms Strategic Collaboration with Launch Therapeutics to Advance Upacicalcet through Pivotal Phase 3 StuPathalys Pharma raised $150 million in secured product financing and equity led by Abingworth, with Carlyle and OrbiMed joining. The company also formed a collaboration with Launch Therapeutics to advance upacicalcet through phase 3 trials for secondary hyperparathyroidism in hemodialysis patients. The financing is expected to fully fund the trials and pre-commercialization activities.Venture Capital Access OnlinePathalys Pharma Raises $150 Million in Secured Product Financing and Equity led by Abingworth; Forms Strategic Collaboration with Launch Therapeutics to Advance Upacicalcet through Pivotal Phase 3 StuPathalys Pharma has secured $150 million in product financing and equity led by Abingworth to support phase 3 clinical trials of its treatment upacicalcet for secondary hyperparathyroidism. The collaboration with Launch Therapeutics aims to advance upacicalcet through significant clinical trials, with both companies contributing their resources toward this goal. Pathalys retains worldwide rights to the product, excluding Japan and Asia, and is positioned to complete its regulatory and commercialization efforts for upacicalcet.PathalysPathalys Pharma Raises $150 Million in Secured Product Financing and Equity led by Abingworth; Forms Strategic Collaboration with Launch Therapeutics to Advance Upacicalcet through Pivotal Phase 3 StuPathalys Pharma raised $150 million in secured product financing and equity, led by Abingworth, to fund pivotal Phase 3 trials for its drug upacicalcet. The company also announced a strategic collaboration with Launch Therapeutics to manage the clinical development of upacicalcet for secondary hyperparathyroidism in hemodialysis patients.BioSpacePathalys Pharma Raises $150 Million in Secured Product Financing and Equity led by Abingworth; Forms Strategic Collaboration with Launch Therapeutics to Advance Upacicalcet through Pivotal Phase 3 StuPathalys Pharma announced a $150 million financing round led by Abingworth to fully fund Phase 3 clinical trials and pre-commercialization activities for its drug upacicalcet. The company simultaneously formed a strategic collaboration with Launch Therapeutics, which will lead the operational execution of these trials while Pathalys retains commercial rights outside Japan. This partnership aims to accelerate regulatory approval in the U.S. for treating secondary hyperparathyroidism in hemodialysis patients.